Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs

Antimicrob Agents Chemother. 1994 Oct;38(10):2477-9. doi: 10.1128/AAC.38.10.2477.

Abstract

The mutations in the quinolone resistance-determining region of the gyrA and gyrB genes from 27 clinical isolates of Escherichia coli with a range of MICs of ciprofloxacin from 0.007 to 128 micrograms/ml and of nalidixic acid from 2 to > 2,000 micrograms/ml were determined by DNA sequencing. All 15 isolates with ciprofloxacin MICs of > or = 1 micrograms/ml showed a change in Ser-83 to Leu of GyrA protein, whereas in clinical isolates with a MIC of > or = 8 micrograms/ml (11 strains), a double change in Ser-83 and Asp-87 was found. All isolates with a MIC of nalidixic acid of > or = 128 micrograms/ml showed a mutation at amino acid codon Ser-83. Only 1 of the 27 clinical isolates of E. coli analyzed showed a change in Lys-447 of the B subunit of DNA gyrase. A change in Ser-83 is sufficient to generate a high level of resistance to nalidixic acid, whereas a second mutation at Asp-87 in the A subunit of DNA gyrase may play a complementary role in developing the strain's high levels of ciprofloxacin resistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Base Sequence
  • Ciprofloxacin / pharmacology*
  • DNA Gyrase
  • DNA Topoisomerases, Type II / genetics*
  • Drug Resistance, Microbial
  • Escherichia coli / drug effects*
  • Escherichia coli / genetics
  • Microbial Sensitivity Tests
  • Molecular Sequence Data
  • Mutation*

Substances

  • Ciprofloxacin
  • DNA Gyrase
  • DNA Topoisomerases, Type II